Mirabegron + Placebo

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Lower Urinary Tract Symptoms

Conditions

Lower Urinary Tract Symptoms, Bladder Outlet Obstruction

Trial Timeline

Dec 1, 2006 → Aug 1, 2008

NCT ID

NCT00410514

About Mirabegron + Placebo

Mirabegron + Placebo is a phase 2 stage product being developed by Astellas Pharma for Lower Urinary Tract Symptoms. The current trial status is completed. This product is registered under clinical trial identifier NCT00410514. Target conditions include Lower Urinary Tract Symptoms, Bladder Outlet Obstruction.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04641975	Phase 3	Terminated	Mar 15, 2021	Jul 24, 2023	Overactive Bladder (OAB)
NCT02787083	Phase 3	Terminated	Aug 1, 2016	Jul 5, 2019	Cystitis, Interstitial
NCT02216214	Approved	Completed	Oct 7, 2014	Jan 2, 2018	Overactive Bladder (OAB)
NCT02086188	Approved	Completed	May 1, 2014	Jun 1, 2019	Multiple Sclerosis
NCT02092181	Approved	Completed	Mar 1, 2014	Jul 1, 2018	Parkinsons Disease
NCT01284309	Phase 1	Completed	Nov 1, 2010	Feb 1, 2011	Intraocular Pressure
NCT00912964	Phase 3	Completed	Apr 28, 2009	Apr 27, 2010	Urinary Bladder, Overactive
NCT00662909	Phase 3	Completed	Mar 28, 2008	Apr 22, 2009	Urinary Bladder, Overactive
NCT00410514	Phase 2	Completed	Dec 1, 2006	Aug 1, 2008	Lower Urinary Tract Symptoms

Competing Products

20 competing products in Lower Urinary Tract Symptoms

See all competitors

Product	Company	Stage	Hype Score
JSP191	Jasper Therapeutics	Phase 1	25
solifenacin succinate + tamsulosin hydrochloride + Placebo to solifenacin + Placebo to tamsulosin	Astellas Pharma	Phase 2	52
Solifenacin	Astellas Pharma	Pre-clinical	23
Tamsulosin + Solifenacin	Astellas Pharma	Approved	85
Vesitirim™ (Solifenacin)	Astellas Pharma	Pre-clinical	23
tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg) + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)	Astellas Pharma	Phase 3	77
tamsulosin hydrochloride + solifenacin succinate + Placebo	Astellas Pharma	Phase 2	52
Tamsulosin + Solifenacin	Astellas Pharma	Approved	85
Tamsulosin OCAS	Astellas Pharma	Approved	85
Duloxetine	Shionogi	Phase 3	77
Duloxetine + Placebo	Shionogi	Phase 3	77
AZD1656	AstraZeneca	Phase 1	33
Nirsevimab + Placebo	AstraZeneca	Phase 3	77
RSVpreF + Placebo	Pfizer	Phase 3	76
Gabapentin	Pfizer	Approved	84
Erythropoiesis-stimulating agents (ESAs) + Luspatercept + Lenalidomide + Hypomethylating agents (HMAs) + Reb blood cell transfusion	Bristol Myers Squibb	Pre-clinical	22
ALX-0171 1.5 mg/kg	Sanofi	Phase 2	51
ALX-0171 3.0 mg/kg + ALX-0171 6.0 mg/kg + ALX-0171 9.0 mg/kg	Sanofi	Phase 2	51
ALX-0171 Dose 1 + ALX-0171 Dose 2 + Placebo	Sanofi	Phase 2	51
Placebo + Hydrocodone bitartrate	UCB	Phase 3	74

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved

micafungin + voriconazoleApproved

mirabegron + solifenacinApproved

Zolpidem (Myslee®) + placeboApproved

TacrolimusApproved